- Home
- ADPT vs QNST Comparison
ADPT vs QNST Comparison
Compare ADPT & QNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- QNST
- Stock Information
- Founded
- ADPT 2009
- QNST 1999
- Country
- ADPT United States
- QNST United States
- Employees
- ADPT N/A
- QNST N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- QNST Business Services
- Sector
- ADPT Health Care
- QNST Consumer Discretionary
- Exchange
- ADPT Nasdaq
- QNST Nasdaq
- Market Cap
- ADPT 1.1B
- QNST 1.1B
- IPO Year
- ADPT 2019
- QNST 2010
- Fundamental
- Price
- ADPT $7.33
- QNST $16.07
- Analyst Decision
- ADPT Strong Buy
- QNST Strong Buy
- Analyst Count
- ADPT 5
- QNST 7
- Target Price
- ADPT $9.40
- QNST $28.86
- AVG Volume (30 Days)
- ADPT 2.4M
- QNST 651.0K
- Earning Date
- ADPT 05-01-2025
- QNST 05-07-2025
- Dividend Yield
- ADPT N/A
- QNST N/A
- EPS Growth
- ADPT N/A
- QNST N/A
- EPS
- ADPT N/A
- QNST N/A
- Revenue
- ADPT $178,957,000.00
- QNST $928,723,000.00
- Revenue This Year
- ADPT $21.20
- QNST $80.76
- Revenue Next Year
- ADPT $22.06
- QNST $9.11
- P/E Ratio
- ADPT N/A
- QNST N/A
- Revenue Growth
- ADPT 5.10
- QNST 68.98
- 52 Week Low
- ADPT $2.28
- QNST $14.39
- 52 Week High
- ADPT $9.01
- QNST $26.27
- Technical
- Relative Strength Index (RSI)
- ADPT 43.95
- QNST 41.36
- Support Level
- ADPT $7.38
- QNST $14.95
- Resistance Level
- ADPT $8.30
- QNST $16.48
- Average True Range (ATR)
- ADPT 0.75
- QNST 1.17
- MACD
- ADPT -0.04
- QNST 0.05
- Stochastic Oscillator
- ADPT 33.85
- QNST 41.58
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About QNST QuinStreet Inc.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia.